280 related articles for article (PubMed ID: 27733759)
41. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.
Murphy G; Lisnevskaia L; Isenberg D
Lancet; 2013 Aug; 382(9894):809-18. PubMed ID: 23972423
[TBL] [Abstract][Full Text] [Related]
42. Novel biological treatments for systemic lupus erythematosus: current and future modalities.
Bezalel S; Asher I; Elbirt D; Sthoeger ZM
Isr Med Assoc J; 2012 Aug; 14(8):508-14. PubMed ID: 22977972
[TBL] [Abstract][Full Text] [Related]
43. New targets in systemic lupus (part 2/2).
Sifuentes Giraldo WA; García Villanueva MJ; Boteanu AL; Lois Iglesias A; Zea Mendoza AC
Reumatol Clin; 2012; 8(5):263-9. PubMed ID: 22483664
[TBL] [Abstract][Full Text] [Related]
44. CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.
Favoino E; Prete M; Marzullo A; Millo E; Shoenfeld Y; Perosa F
Clin Rev Allergy Immunol; 2017 Apr; 52(2):217-233. PubMed ID: 27216429
[TBL] [Abstract][Full Text] [Related]
45. [The metabolic regulation in immune cells and pathogenesis of systemic lupus erythematosus ∼toward new therapeutic applications∼].
Takeshima Y; Iwasaki Y; Okamura T; Fujio K; Yamamoto K
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):12-20. PubMed ID: 28539549
[TBL] [Abstract][Full Text] [Related]
46. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
47. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
[TBL] [Abstract][Full Text] [Related]
48. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
49. Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
Chin P; Chan AC
Biochemistry; 2018 Feb; 57(5):474-476. PubMed ID: 29172456
[No Abstract] [Full Text] [Related]
50. Pathways leading to an immunological disease: systemic lupus erythematosus.
Zharkova O; Celhar T; Cravens PD; Satterthwaite AB; Fairhurst AM; Davis LS
Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i55-i66. PubMed ID: 28375453
[TBL] [Abstract][Full Text] [Related]
51. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.
Touma Z; Gladman DD
Lupus Sci Med; 2017; 4(1):e000239. PubMed ID: 29344386
[TBL] [Abstract][Full Text] [Related]
52. Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses.
Chen Y; Sun J; Zou K; Yang Y; Liu G
Rheumatol Int; 2017 Jul; 37(7):1089-1099. PubMed ID: 28493175
[TBL] [Abstract][Full Text] [Related]
53. Drivers of the immunopathogenesis in systemic lupus erythematosus.
Rose T; Dörner T
Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):321-333. PubMed ID: 29224674
[TBL] [Abstract][Full Text] [Related]
54. Immunometabolism in systemic lupus erythematosus.
Morel L
Nat Rev Rheumatol; 2017 May; 13(5):280-290. PubMed ID: 28360423
[TBL] [Abstract][Full Text] [Related]
55. Diagnosis and treatment of postoperative chyle leakage via percutaneous transabdominal catheterization of the cisterna chyli: a preliminary study.
Cope C
J Vasc Interv Radiol; 1998; 9(5):727-34. PubMed ID: 9756057
[TBL] [Abstract][Full Text] [Related]
56. Medium-chain triglycerides: an update.
Bach AC; Babayan VK
Am J Clin Nutr; 1982 Nov; 36(5):950-62. PubMed ID: 6814231
[TBL] [Abstract][Full Text] [Related]
57. New insights into the immunopathogenesis of systemic lupus erythematosus.
Tsokos GC; Lo MS; Costa Reis P; Sullivan KE
Nat Rev Rheumatol; 2016 Nov; 12(12):716-730. PubMed ID: 27872476
[TBL] [Abstract][Full Text] [Related]
58. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of IL-17 ameliorates systemic lupus erythematosus in Roquin
Lee SY; Lee SH; Seo HB; Ryu JG; Jung K; Choi JW; Jhun J; Park JS; Kwon JY; Kwok SK; Youn J; Park SH; Cho ML
Sci Rep; 2019 Mar; 9(1):5227. PubMed ID: 30914691
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies.
Chasov V; Zmievskaya E; Ganeeva I; Gilyazova E; Davletshin D; Khaliulin M; Kabwe E; Davidyuk YN; Valiullina A; Rizvanov A; Bulatov E
Antibodies (Basel); 2024 Feb; 13(1):. PubMed ID: 38390871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
